Clin2
NCT07029581Possibly a fitRecruiting

Testing ACP-204 for psychosis in Lewy body dementia

Lewy Body Dementia Psychosis

Treatments studied

Part of Brain & nervous system, Mental health clinical trials.

This trial tests a new drug called ACP-204 for people with dementia from Lewy body disease or Parkinson's who also have hallucinations or delusions. The goal is to see if the drug can safely reduce these symptoms without worsening thinking problems.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
180 people
Ages
55 years to 84 years
Study type
Interventional

Who can take part

  • You are between 55 and 85 years old.
  • You have either Parkinson's disease with dementia or dementia with Lewy bodies.
  • You are experiencing hallucinations or delusions because of your dementia.
  • You are not in hospice or bedridden, and you are not suicidal.
  • You don't have serious heart, lung, or other unstable medical conditions that would interfere with the study.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07095465Enrolling by invitation· Phase 3
Long-term study of ACP-204 for psychosis in Lewy body dementia

This study tests a medication called ACP-204 for psychosis (hallucinations or delusions) in people with Lewy body dementia. It is a long-term extension open to patients who completed a previous ACP-204 study, to see if the drug continues to be helpful and safe.

Irvine, California
NCT06194799Enrolling by invitation· Phase 3
Long-term ACP-204 for Alzheimer's psychosis

This study tests a long-term medicine (ACP-204) for people with Alzheimer's disease who also have psychosis (hallucinations or delusions). If you took part in the earlier ACP-204 study, this open-label extension lets you continue receiving the medicine to see how well it works over time.

Costa Mesa, California
NCT06540833Recruiting· Phase 2
Study of ITI-1284 for psychosis in Alzheimer's disease

This trial tests an experimental drug, ITI-1284, to see if it can safely reduce psychosis (hallucinations or delusions) in people with Alzheimer's disease. It may be an option for patients who have both Alzheimer's and related psychotic symptoms.

Anaheim, California
NCT06159673Recruiting· Phase 2/Phase 3
ACP-204 for Alzheimer's with psychosis

This study tests a new medicine called ACP-204 for people with Alzheimer's disease who also have psychosis (like seeing or hearing things that aren't real). It aims to see if the drug can help reduce these symptoms safely.

Chandler, Arizona
NCT07284290Recruiting· Phase 4
Brain imaging, thinking, and medication study for Lewy body dementia

This study looks at how brain changes affect attention and thinking in people with Lewy body dementia. It includes brain scans, an EEG, and a medication option to see if it helps with symptoms.

Richmond, Virginia
NCT06537076Recruiting· Phase 2
Testing AR1005 for Lewy body dementia

This trial tests an experimental oral medication called AR1005 for people with Lewy body dementia or its early stage. It aims to see if the drug is safe and helps with memory, thinking, and daily function.

Seoul

Hear when a new Lewy Body Dementia Psychosis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.